Filing Flows

Filing Flows › Aligos Therapeutics (ALGS) › Next earnings date

Aligos Therapeutics (ALGS) earnings: beat the estimate

Aligos Therapeutics (ALGS) reported on Nov 6, 2026 and beat the EPS estimate: −$2.09 against −$2.53 (+17.4%). Revenue was $2.8M for Q3 2026, +282% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+17.4% vs estimate
Beat rate80%

The last report

Aligos Therapeutics reported revenue of $2.8M for the third quarter 2026 (+282% Y/Y), net loss $21.9M. How it makes money → · Every quarter →

Aligos Therapeutics: EPS against the estimate, last 5 reportsAligos Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$2.01−$3.04Nov 25−$2.49−$1.91Mar 26−$2.25−$2.21May 26−$1.24−$0.14Aug 26−$2.53−$2.09Nov 26
Latest (Nov 26): Estimate −$2.53, Reported −$2.09.
ALGS: the stock's move on each reportALGS: the stock's move on each reportAug 6, 2026+17.9%May 7, 2026+1.1%Mar 5, 2026+1.7%Nov 6, 2025-3.5%

Aligos Therapeutics' latest quarter

Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.

Questions

Did Aligos Therapeutics beat earnings?

Aligos Therapeutics (ALGS) reported on Nov 6, 2026 and beat the EPS estimate: −$2.09 against −$2.53 (+17.4%).

When does ALGS report earnings?

The next date is not set yet.

Does Aligos Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.